High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Status:
Active, not recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Rationale:The purpose of this research study is to test the effectiveness of the standard
high dose cytarabine (HiDAC) on days 1 through 5 followed by a single dose of pembrolizumab
on day 14 as induction therapy in patients with relapsed and refractory acute myeloid
leukemia (AML). Patients who achieve a response to treatment will continue on the study drug
(pembrolizumab) every 3 weeks for up to 2 years maintenance therapy.
Purpose:This is a study about a new investigative drug, pembrolizumab (MK-3475) that is being
studied in a clinical research trial together with standard chemotherapy (HiDAC) in relapsed
and refractory AML. The study will also explore the association between potential immune
biomarkers and clinical outcomes with pembrolizumab; therefore all patients will have blood
and bone marrow samples collected before and after treatment to determine the dynamic nature
of immune signatures pre and post-treatment.